<div id="readability-page-1"><div><p>(MT Newswires) -- Johnson &amp; Johnson (JNJ) and Roche are among the firms in discussions with Shanghai Henlius Biotech to buy the rights to its HLX43 experimental cancer drug, Bloomberg News reported Tuesday, citing people familiar with the matter.</p><p> If the deal goes through, the Shanghai Fosun Pharmaceutical unit could receive at least several hundred million dollars up front, with potentially more in milestone payments depending on the drug's performance, the unnamed sources told the news outlet.</p><p> HLX43 is in mid-stage testing in China, according to the report.</p><p> Johnson &amp; Johnson, Roche, and Shanghai Henlius Biotech didn't immediately respond to MT Newswires' requests for comment.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></div></div>

强生

罗氏(ADR)

复宏汉霖

<p>强生和罗氏正在与上海复宏汉霖生物科技进行谈判，计划收购 HLX43 实验性癌症药物的权利。如果谈判成功，上海复星医药可能会获得数亿美元的预付款，以及基于该药物表现的额外里程碑付款。HLX43 目前正在中国进行中期测试。各公司尚未对该讨论发表评论</p>

强生公司正在与其他公司进行谈判，以获得上海复宏汉霖实验性抗癌药的使用权